Search

Your search keyword '"Coats, Andrew"' showing total 30 results
Start Over Author "Coats, Andrew" Journal circulation
30 results on '"Coats, Andrew"'

3. Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure

Author

Hartmann, Franz, primary, Packer, Milton, additional, Coats, Andrew J.S., additional, Fowler, Michael B., additional, Krum, Henry, additional, Mohacsi, Paul, additional, Rouleau, Jean L., additional, Tendera, Michal, additional, Castaigne, Alain, additional, Anker, Stefan D., additional, Amann-Zalan, Ildiko, additional, Hoersch, Silke, additional, and Katus, Hugo A., additional

Published
2004
Full Text
View/download PDF

6. Variability of Phase Shift Between Blood Pressure and Heart Rate Fluctuations

Author

Halámek, Josef, primary, Kára, Tomáš, additional, Jurák, Pavel, additional, Souček, Miroslav, additional, Francis, Darrel P., additional, Davies, L. Ceri, additional, Shen, Win K., additional, Coats, Andrew J.S., additional, Novák, Miroslav, additional, Nováková, Zuzana, additional, Panovský, Roman, additional, Toman, Jiří, additional, Šumbera, Josef, additional, and Somers, Virend K., additional

Published
2003
Full Text
View/download PDF

7. Uric Acid and Survival in Chronic Heart Failure

Author

Anker, Stefan D., primary, Doehner, Wolfram, additional, Rauchhaus, Mathias, additional, Sharma, Rakesh, additional, Francis, Darrel, additional, Knosalla, Christoph, additional, Davos, Constantinos H., additional, Cicoira, Mariantonietta, additional, Shamim, Waqar, additional, Kemp, Michel, additional, Segal, Robert, additional, Osterziel, Karl Josef, additional, Leyva, Francisco, additional, Hetzer, Roland, additional, Ponikowski, Piotr, additional, and Coats, Andrew J.S., additional

Published
2003
Full Text
View/download PDF

9. Skeletal Muscle Reflex in Heart Failure Patients

Author

Scott, Adam C., primary, Wensel, Roland, additional, Davos, Constantinos H., additional, Georgiadou, Panagiota, additional, Kemp, Michael, additional, Hooper, James, additional, Coats, Andrew J.S., additional, and Piepoli, Massimo F., additional

Published
2003
Full Text
View/download PDF

10. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure

Author

Packer, Milton, primary, Fowler, Michael B., additional, Roecker, Ellen B., additional, Coats, Andrew J.S., additional, Katus, Hugo A., additional, Krum, Henry, additional, Mohacsi, Paul, additional, Rouleau, Jean L., additional, Tendera, Michal, additional, Staiger, Christoph, additional, Holcslaw, Terry L., additional, Amann-Zalan, Ildiko, additional, and DeMets, David L., additional

Published
2002
Full Text
View/download PDF

14. Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure

Author

Doehner, Wolfram, primary, Schoene, Nina, additional, Rauchhaus, Mathias, additional, Leyva-Leon, Francisco, additional, Pavitt, Darrell V., additional, Reaveley, David A., additional, Schuler, Gerhard, additional, Coats, Andrew J.S., additional, Anker, Stefan D., additional, and Hambrecht, Rainer, additional

Published
2002
Full Text
View/download PDF

16. Peripheral Chemoreceptor Hypersensitivity

Author

Ponikowski, Piotr, primary, Chua, Tuan Peng, additional, Anker, Stefan D., additional, Francis, Darrel P., additional, Doehner, Wolfram, additional, Banasiak, Waldemar, additional, Poole-Wilson, Phillip A., additional, Piepoli, Massimo F., additional, and Coats, Andrew J.S., additional

Published
2001
Full Text
View/download PDF

17. Enhanced Ventilatory Response to Exercise in Patients With Chronic Heart Failure and Preserved Exercise Tolerance

Author

Ponikowski, Piotr, primary, Francis, Darrel P., additional, Piepoli, Massimo F., additional, Davies, L. Ceri, additional, Chua, Tuan Peng, additional, Davos, Constantinos H., additional, Florea, Viorel, additional, Banasiak, Waldemar, additional, Poole-Wilson, Philip A., additional, Coats, Andrew J. S., additional, and Anker, Stefan D., additional

Published
2001
Full Text
View/download PDF

27. Augmented Peripheral Chemosensitivity as a Potential Input to Baroreflex Impairment and Autonomic Imbalance in Chronic Heart Failure

Author

Ponikowski, Piotr, primary, Chua, Tuan Peng, additional, Piepoli, Massimo, additional, Ondusova, Daniela, additional, Webb-Peploe, Katharine, additional, Harrington, Derek, additional, Anker, Stefan D., additional, Volterrani, Maurizio, additional, Colombo, Roberto, additional, Mazzuero, Giorgio, additional, Giordano, Amerigo, additional, and Coats, Andrew J. S., additional

Published
1997
Full Text
View/download PDF

30. Efficacy of Left Ventricular Augmentation With Algisyl-LVR in the Treatment of Advanced Heart Failure Patients With Ischemic and Non-ischemic Cardiomyopathy: Results of the AUGMENT-HF Multicenter Randomized Controlled Trial.

Author

Anker, Stefan D., Coats, Andrew, Cristian, Gabriel, Dragomir, Dinu, Pusineri, Enrico, Bettari, Luca, Volterrani, Maurizio, Lee, Randall J., Sabbab, Hani N., Hinson, Andy, and Mann, Douglas L.

Subjects
*HEART failure, *BIOPOLYMERS, *ISCHEMIA
Abstract

Introduction: Therapeutic options for patients with severe heart failure (HF), refractory to pharmacological therapies, are limited. Given the significant morbidity and mortality associated with this stage of the disease, a novel and effective therapeutic approach is greatly needed. Clinically relevant large animal models and computer simulations have suggested that the addition of non-contractile material to the failing myocardium can reduce elevated myofiber stress. Algisyl-LVR is a proprietary bio-polymer gel that is injected into strategic areas of the LV free wall, where it remains as a permanent implant. A prior clinical trial suggested Algisyl-LVR to be safe and potentially efficacious in patients with advanced HF. Hypothesis: Algisyl LVR is superior to standard medical therapy in the management of chronic HF with a reduced ejection fraction (EF) secondary to ischemic or non-ischemic etiologies. Methods: Multi-center, prospective, randomized, controlled evaluation of Algisyl-LVR in patients with HF secondary to either ischemic or non-ischemic etiology. Seventy-eight patients were randomized (1:1) to Algisyl-LVR (n=40) and standard medical therapy (n=38). Patients were mean age 62.3 (±9.6) with ischemic (57.7%) or non-ischemic (42.3%) HF, a mean EF of 25.8 (±5.5), and symptomatic HF (mean NYHA class of 2.9±0.5) with a mean Peak V02 of 12.2 (±1.8) ml/min/kg, and a mean 6 MWT distance of 293.6 (±81.3) m. Patients must have been on stable, evidence-based therapy for HF. Results: The results of the primary endpoint analysis will be presented including 6 month change in Peak V02, 6 MWT, NVHA class, KCCQ score, biochemical analysis, and electrocardiographic evaluations. Conclusions: The results of the AUGMENT-HF clinical trial will provide the first insights into the potential for this novel concept of LV augmentation with Algisyl-LVR in the failing heart as an effective strategy for improving functional capacity and clinical outcomes in patients with advanced HF. [ABSTRACT FROM AUTHOR]

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results